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Abstract
Background: Due to lack of a targeted therapy for the triple-negative breast cancer (TNBC) patients, it is important
to explore this aggressive breast cancer type in more detail and to establish novel therapeutic approaches. TNBC is
defined negative for the protein expression of oestrogen receptor (ER), progesterone receptor (PR) and human
epidermal growth factor receptor 2 (HER2). One prominent feature of this cancer type is the frequent overexpression of
major components of the urokinase-type plasminogen activator system (uPAS) including uPA, its receptor uPAR and
the inhibitor PAI-1, which may be valuable as therapeutic targets.
Methods: Direct interactions of uPAR with interactors were demonstrated by immunoprecipitations and proximity
ligation assays. For stable knockdowns of target proteins, lentiviral vectors were used and the effects were analysed by
immunoblottings and using in vitro cell viability, migration and invasion assays. Immunohistochemical and statistical
analyses of biomarkers and clinical parameters were conducted in a TNBC cohort (n = 174).
Results: Direct tumour-promoting interactions of uPAR with uPA and the insulin-like growth factor receptor 1 (IGF1R)
were shown in TNBC cells and these interactions were significantly reduced (p = 0.001) when uPAR was
downregulated. The combined knockdown of uPAR and uPA or IGF1R additively and significantly reduced cell viability,
migration and invasion of the model cell lines. In TNBC tissue, the complexes formed by uPAR with uPA or with IGF1R
significantly correlated with the histological grade (p = 0.0019) as well as with cathepsin B and D (p≤ 0.0001) that are
implicated in cell invasion and metastasis.
Conclusions: Our outcomes show that not only overexpressed biomarkers promote tumourigenesis, but rather their
interactions further potentiate tumour progression. This study emphasises the potential of combined approaches
targeting uPAR and its interactors with regard to an improved therapy of TNBC.
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Background
In TNBC, there is a lack of protein expression of the
oestrogen receptor (ER) and the progesterone receptor
(PR) as well as a weak or absent protein expression of
the human epidermal growth factor receptor 2 (HER2)
[1]. TNBC is the most aggressive tumour type among
breast cancers that is associated with a poor prognosis
and occurs in approximately 10 to 20 % of invasive
breast cancers [2]. Due to the lack of targeted therapies,
the patients are treated systemically leading to severe
side effects and besides that the therapy efficacy is lim-
ited; therefore novel therapeutic targets are strongly
needed. Several research groups revealed insulin recep-
tor (IR), insulin-like growth factor receptor 1 (IGF1R),
epidermal growth factor receptor (EGFR), hepatocyte
growth factor receptor (c-Met) and in particular the
urokinase-type plasminogen activator (uPA) with its re-
ceptor (uPAR) to be overexpressed in many tumour en-
tities including TNBC [3–9]. Except uPAR, these
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transmembrane receptors are activated by the binding of
growth factors to their extracellular domain, followed by
the formation of homo- and/or heterodimers, which in-
duce phosphorylation of the intracellular receptor do-
mains and recruit further signalling molecules to initiate
signalling cascades within the cells [10, 11].
The receptors IR, IGF1R, EGFR and c-Met promote cell
proliferation, invasion, survival and metastasis by activating
the phosphatidylinositol 3-kinase (PI3K), Akt, mTOR path-
way as well as the Ras, Raf, mitogen-activated protein kin-
ase (MAPK), extracellular signal-regulated kinase (ERK)
pathway and the signal transducer and activator of tran-
scription (STAT) 3-mediated signalling [4, 12, 13]. uPAR is
strongly involved in wound healing, clot lysis, tissue remod-
eling through binding to and activating pro-uPA, which in
turn stimulates further invasion-promoting factors such as
plasminogen and pro-matrixmetalloproteases (pro-MMPs)
followed by the degradation of the extracellular matrix
(ECM) leading to migration and invasion of tumour cells
[14]. It has been shown that strongly invasive TNBC cells
and respective cell lines use this natural process and en-
hance their invasive capacity through overexpression of
uPAR, uPA or MMPs [9, 15]. Depending on their cellular
context and expression levels, IR, IGF1R, EGFR, c-Met and
uPAR promote malignancy also through cooperating with
each other and may be promising candidates for an im-
proved cancer therapy [13]. Since uPAR is solely associated
to the plasma membrane by a glycosylphosphatidyl inositol
(GPI) anchor, interactions with membrane-spanning
receptors may enable uPAR-mediated intracellular
signalling as well.
Considering IGF1R and IR inhibition, many attempts
have been made with respect to targeted therapies, in-
cluding several receptor tyrosine kinase inhibitors
(RTKIs), monoclonal humanised antibodies or IGF-
binding proteins [3]. However, the therapeutic ap-
proach turned out to be less successful than expected.
Due to high homology on DNA and protein level [16],
a cross talk between IGF1R and IR signalling is sup-
posed to diminish the inhibitory effects [10]. Another
challenge is the role of IR, which is significantly in-
volved in glucose metabolism and therefore could not
be completely blocked [10]. EGFR-targeted therapeutic
antibodies such as cetuximab or panitumumab or the
TKIs gefitinib and erlotinib were applied in vitro and
in clinical trials with TNBC patients indicating a suc-
cessful therapy, however, mostly combinational ap-
proaches, also with chemotherapeutics, were more
effective [17–22]. Anti-c-Met-based therapy using
antibodies or tyrosine kinase inhibitors are currently
tested in phase II clinical trials in TNBC patients [23–25].
Nevertheless, the success of RTKIs for cancer therapy is
also limited due to intrinsic or acquired resistance by
cancer cells [26].
In addition, therapeutic approaches have been made
towards the uPA system (uPAS) components such as
uPA, uPAR or PA inhibitor-1 (PAI-1). In particular in
breast cancer, uPA and PAI-1 have been validated as pre-
dictive or prognostic biomarkers and in vivo experi-
ments emphasise anti-tumour effects when uPA-uPAR
interactions or uPA alone were inhibited [27–30]. uPAR
was also knocked down in combination with the RNAi
of uPA, HER2 or MMP9 or combined with Trastuzumab
in different breast cancer cell lines and in in vivo studies
resulting in reduced cell migration, invasion, angiogen-
esis or proliferation [31–33]. Co-overexpression of uPA,
uPAR and IGF1R elevated the malignancy of pancreatic,
hepatocellular, rhabdomyosarcoma, colon and breast
cancer cells [6, 34–36].
To date, little is known regarding the role of uPAR
and IGF1R in TNBC and whether these receptors dir-
ectly interact with each other. In this study, to investi-
gate in more detail the impact of these receptors in
TNBC, uPAR, uPA and IGF1R were stably and simultan-
eously knocked down in two TNBC cell lines and the ef-
fects on in vitro cell migration, invasion, proliferation
and on signalling molecules were examined. Further-
more, immunohistochemical analyses and PLA also
using TNBC tissue samples (n = 174) demonstrate a dir-
ect interaction of uPAR with uPA and with IGF1R em-




The following human breast cancer cells lines MDA-MB-
361 (HTB-27), SKBR3 (HTB-30), T47D (HTB-133) were
acquired from American Type Culture Collection (ATCC)
and MCF7 (ACC115) cells from German Collection of
Microorganisms and Cell Cultures, DSMZ). The BT549
and MDA-MB-231 cell lines are a kind gift from Prof. M.
Schmitt, Clinical Research Unit, Department of Obstetrics
and Gynecology, Technische Universität München). The
BT549, T47D and MCF7 cells were maintained in RPMI
1640 with GlutaMAX (Rosewell Park Memorial Institute
medium) supplemented with bovine insulin (10 μg/μl,
Sigma, St. Lois, MO, USA). The SKBR3 and MDA-MB-
361 cells were maintained in DMEM with GlutaMAX
(Dulbecco Modified Eagles medium) that was additionally
supplemented with non-essential amino acids (Life
Technologies, Darmstadt, DE) for cultivation of MDA-
MB-231 cells. Both media were supplemented with 10 %
fetal calf serum (FCS, Invitrogen, Carlsbad, CA, USA) and
0.25 % of each penicillin and streptomycin (Life Technolo-
gies, Darmstadt, DE). The cells were maintained in a water
humidified 37 °C incubator with 5 % CO2. The last cell
line authentication was conducted before starting the ex-
periments as described previously [37].
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Lentiviral transductions of breast cancer cell lines
SMARTchoice™ lentiviral shRNA vectors (GE Healthcare
Lafayette, CO, USA) were used for transductions for
RNAi of uPAR (VSH6063, SH-006388-01, −02, −03),
uPA (VSH6063, SH-006000-01, −02, −03), IGF1R
(VSH6063, SH07-003012-04, −05, −06). For efficient
knockdown of the target proteins, a pool of three viral
particles (targeting three different fragments within the
RNA sequence of the target protein), each at a multipli-
city of infection (MOI) of 30, was used. All viral particles
were tested for knockdown specificity and efficiency be-
fore starting the RNAi experiments. A total of 3.0 × 104
BT549 or MDA-MB-231 cells were seeded into each
well of a 12-well plate and after 42 h infected with the
lentiviral vectors for the knockdown of uPAR (uPAR_R-
NAi), of uPA (uPA_RNAi) and of IGF1R (IGF1R_RNAi).
For a successful knockdown of the strongly overex-
pressed uPAR, respective infection was repeated several
times as described [38]. A vector containing a non-
targeting sequence (SMARTvector 2.0 non-targeting par-
ticle) was used as negative control and a vector for
GAPDH knockdown was used as positive control
(SMARTvector 2.0 Human GAPD). For enhancing the
infection, 2 μg/ml polybrene (Invitrogen, Carlsbad, CA,
USA) was added to each approach as described [39]. All
infections were conducted in triplicates.
Quantitative reverse transcription-PCR (qRT-PCR)
The RNA isolation, TaqMan assays and analysis were
conducted as described [40]. Quantitative PCR was
conducted in triplicates using TaqMan probes: uPAR
(Hs00958880_m1), uPA (Hs01547054_m1) and IGF1R
(Hs00609566_m1, Thermo Fisher, Waltham, Massachu-
setts, USA). The mRNA expression levels were calculated
by the 2–ΔΔCT method and normalised to the control
(HPRT1) and to MCF7 cells (calibrator).
Western blot analysis
The analysis and quantification of protein expressions or
phosphorylations of uPAR [41], uPA, PAI-1, IGF1R, IR,
c-Met, Paxillin, 44/42 MAPK, HER2, PR, ER, STAT3,
p27Kip1, MMP2, MMP 9, GAPDH and Tubulin were
analysed using primary antibodies (Additional file 1:
Table S1) as described previously [42].
Immunoprecipitations
To determine potential interaction partners of uPAR, di-
verse immunoprecipitation protocols were established
using the goat polyclonal anti-uPAR antibody (AF807,
R&D Systems, Minneapolis, MN, USA) for 60 min at 4 °C
based on previously described procedure [43]. As negative
control, a polyclonal goat isotype antibody was applied.
The precipitated proteins were eluted with Laemmli buffer
(2×) and further used for Western Blot analysis.
Wound scratch migration assay
To analyse the knockdown effects on in vitro cell migra-
tion, migration assays were conducted in six-well plates
under serum-reduced conditions (0,1 % FBS) and the
open areas were quantified using TScratch software as
described [39]. The migration assays were conducted in
triplicates and the Student’s t-test was used for statistical
analysis.
Invasion assays
To analyse the knockdown effects on in vitro cell inva-
sion, 2.0 × 104 control or infected BT549 or MDA-MB-
231 cells were seeded in serum-reduced medium
(0,1%FBS) in matrigel-coated chambers, inserted into
24-well cell culture plates and incubated for 48 h at 37 °C.
The invasion assays were conducted according to manu-
facturers’ protocol and quantified by counting the invaded
cells in 13 representative images. The invasion assays were
conducted in triplicates and the means of each approach
were quantified in relation to the mock control. The
Student’s t-test was used for statistical analysis.
WST-1 cell proliferation assay
To analyse the knockdown effects on in vitro cell prolif-
eration, 1.0 × 104 control or infected BT549 or MDA-
MB-231 cells per well were seeded in a 96-well culture
plate and the water soluble tetrazolium WST-1 assay
(Roche Diagnostics, Mannheim, DE) was conducted in
quintuplicate as described previously [37]. The Student’s
t-test was used for statistical analysis.
Generation of formalin-fixed and paraffin-embedded
(FFPE) cell line blocks
To optimise the analysis of protein expressions and of
protein complexes in cell lines and tumour samples,
control and uPAR-depleted MDA-MB-231cell line
blocks were generated as described previously [44].
Patients and tumour specimens
Formalin-fixed, paraffin-embedded breast cancer tissues of
the TNBC type (n = 174) were collected at the Department
of Gynecology and Obstetrics, Klinikum rechts der Isar,
Technische Universität München, Germany. Written in-
formed consent for the use of tissue samples for research
purposes was obtained from all the patients. Approval for
use of the tumour samples was given from the Ethics Com-
mittee of the Medical Faculty of the Technische Universität
München, Germany.
The negative or only low protein expression of HER2
and of the steroid hormone receptors (ER, PR) in
tumour tissues was verified by immunohistochemical
analysis as described below. The other parameters of the
174 tumours are as following, in total, 90 tumours were
node-negative. Concerning tumour size, 52 tumours
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were less than 2 cm, 93 were between 2 and 5 cm, and
29 tumours were more than 5 cm in size. The most tu-
mours were classified as grade 3 (n = 150), followed by
21 cases as grade 2, and 3 cases as grade 1 [45]. From 68
patients, data concerning breast cancer 1 mutation were
available. The median follow-up of patients was
57 months (max. 244 months), with 52 (30 %) patients
suffering from metastases within the period of clinical
follow-up. All tumour patients were surgically treated
and 108 of the patients received adjuvant chemotherapy.
Generation of tissue microarrays (TMAs)
TMAs were generated with a tissue-arraying instrument
(Beecher Instruments Inc., Silver Spring, MD, USA) as
described [46]. Three micrometer thick sections were
cut from the TMA blocks and both, the TMA and the
punched block were re-examined to validate representa-
tive sampling.
Immunohistochemical (IHC) analysis
Immunohistochemical analysis was performed on 3 μm
thick sections of the FFPE cell blocks and of tumour
tissues using an automated stainer (Discovery XT) and
a DAB Map kit (both Ventana Medical Systems,
Tucson, AZ, USA) as described [46]. The applied anti-
bodies targeting uPAR, uPA, PAI-1, IGF1R, IR, c-Met,
HER2, PR, ER, Plasminogen, Ki67, uPARAP, PTEN,
p27Kip1, Cathepsin B and D are listed in Additional file 1:
Table S1. The stained TMA specimens were assessed and
scored by two independent observers using a 4-point scale
(0–3+) [46].
Proximity ligation assay (PLA) technique on FFPE sections
For the visualisation of protein complexes with inter-
action partners of uPAR, the PLA technique was con-
ducted on cell line blocks and on TMAs from tumour
samples using the DUOLinkTM kit (OLINK, Uppsala, S)
according to the manufacturer’s instruction as described
[39, 47]. The primary antibodies targeting uPAR, uPA
and IGF1R were the same, which were applied for IHC
analysis. For the quantification of PLA, the slides were
scanned and signals were evaluated as described previ-
ously [47]. For each protein complex, signals of three
visual fields per figure were calculated and subjected to
statistical analysis.
Statistical analysis of tumour tissues
The correlations between experimental parameters and
histopathological parameters were examined with Spear-
man’s rank correlation test. In all tests, statistical signifi-
cance was considered when p ≤ 0.05.
Results
uPAR, IGF1R and c-Met are significantly co-overexpressed
in TNBC samples and breast cancer cell lines
To select TNBC tumour samples for this study, the ex-
pression of markers of the uPA system and related
tumour-promoting proteins was determined by IHC
analysis. The three major components of the uPAS in-
cluding uPA, uPAR and PAI-1 as well as IGF1R, IR and
c-Met are highly expressed and mostly localised on the
cell membrane and in the cytoplasm (Fig. 1a and b). In
contrast, ER, PR and HER2 are not or moderately
expressed in this TNBC cohort. In addition, for the iden-
tification of model breast cancer cell lines representative
for TNBC, the protein expressions were determined by
immunoblotting. Out of seven breast cancer cell lines
analysed here, only the BT549 and MDA-MB-231 cells
(strongly) express uPA and uPAR. The IGF1R and the
paxillin protein expression levels are higher in MDA-
MB-231 than in BT549 cells and the phosphorylated c-
Met could only be detected in MDA-MB-231 cells,
whereas the protein expressions of ER and PR were ab-
sent and of HER2 very weak in these TNBC cell lines
(Fig. 1c).
The combined knockdown of uPAS components and of
IGF1R significantly impairs tumour cell proliferation,
migration and invasion in vitro
To investigate whether the knockdown of uPAS compo-
nents and associated signalling proteins impairs the
tumour progression of BT549 and MDA-MB-231 cells
in vitro, uPAR, uPA and IGF1R were transiently down-
regulated, also in combination, in BT549 cells using sev-
eral targeting and control small interfering RNAs
(siRNAs, Additional file 2: Figure S1a and Additional file
3: Figure S2a). Transient RNAi of the target proteins
and/or in combination significantly reduced in vitro cell
viability, migration and invasion 48 h post-transfection
(Additional file 2: Figure S1b-e and Additional file 3:
Figure S2b-e). The expression of the invasion-promoting
proteins MMP2, MMP9 or paxillin and the phosphoryl-
ation of STAT3 were reduced following uPAR RNAi
alone or in combination with RNAi of uPA or IGF1R
(Additional file 2: Figure S1b and Additional file 3:
Figure S2b).
For long-term analysis of tumour progression follow-
ing the knockdown of uPAS components and IGF1R
with regard to an improved breast cancer therapy, the
target proteins were stably downregulated. The cells
were incubated for up to 8 weeks and the effects were
determined using in vitro assays and immunoblottings.
Successful and specific knockdown of the target proteins
uPAR, IGF1R and uPA was confirmed by qRT-PCR
(Additional file 3: Figure S2f) and by Western blots
(Fig. 2a). GAPDH-RNAi was used as a positive control
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of optimal infection conditions for the cell lines and a
non-targeting shRNA sequence within the lentiviral vec-
tor was used as negative control. GAPDH-RNAi led to a
strong inhibition of proliferation of BT549 cells; there-
fore, these approaches could not be used for respective
assays and are not shown. Apart from that, the used
control shRNAs do not show any unspecific effects re-
garding the protein and RNA levels in both cell lines
(Fig. 2a and Additional file 3: Figure S2f).
In MDA-MB-231 cells, RNAi of IGF1R or in combin-
ation with uPAR RNAi or uPA RNAi led to a strongly
reduced phosphorylation of c-Met (Fig. 2a, left). In
BT549 cells, the RNAi of IGF1R or combined with RNAi
of uPAR or uPA led to a reduced phosphorylation of 44/
42 MAPK (Fig. 2a, right). Following uPA RNAi or co-
RNAi of uPA and IGF1R in BT549 cells, the MMP2 pro-
tein expression was diminished (Fig. 2a, right). In both
cell lines, the cell cycle inhibitor p27Kip1 was induced
following single IGF1R knockdown or combined with
RNAi of uPA or uPAR (Fig. 2a), whereas no alteration
on phosphorylation of STAT3 or Akt was observed (data
not shown).
In comparison to the mock control, the cell prolifera-
tion was significantly (p ≤ 0.001) reduced in MDA-MB-
231 cells following RNAi of IGF1R (−70 %) or uPA
(−55 %) and following co-RNAi of uPAR and IGF1R
(−65 %) or of uPA and IGF1R (−50 %) (Fig. 2b, left). In
BT549 cells, compared to the mock control, only uPA-
depleted cells showed a significantly reduced in vitro cell
proliferation (−16 %, p = 0.003, Fig. 2b, right).
Furthermore, compared to MDA-MB-231 mock cells,
the in vitro migration was significantly reduced following
the RNAi of uPAR (−18 %, p < 0.001) and/or IGF1R
(−25 %, p < 0.001, respectively) and uPA (−20 %, p = 0.002)
(Fig. 2c, left, 24 h after starting the assay). More import-
antly, following co-RNAi of IGF1R and uPAR and com-
pared to uPAR RNAi alone, the cell migration was





































Fig. 1 Co-overexpression of uPAS components and tumour-promoting proteins in TNBC samples and cell lines. a Immunohistochemical analysis
of tumour samples showing positive expression and localisation of the proteins of interest: uPAR, uPA, PAI-1, IGF1R, IR and c-Met, bar: 50 μm and
b Protein expressions of uPAR, uPA, PAI-1, IGF1R, IR and c-Met in the TNBC cohort (n = 174). c Immunoblottings of uPAR, uPA (supernatant), PAI-1,
IGF1R, (phospho) c-Met, HER2, ER, PR in two TNBC cell lines: BT549 and MDA-MB-231 and in the breast cancer cell lines: BT474, MCF7, MDA-MB-361,
SKBR3 and T47D. Tubulin was used as loading control











In vitro matrigel invasion assay (n=3)
b
In vitro scratch wound migration assay (n=3)










































































































































































Fig. 2 (See legend on next page.)
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well as following co-RNAi of uPA and IGF1R compared
to uPA RNAi alone (−8 %, p = 0.028) (Fig. 2c, left). Con-
sidering the effects 48 h after starting the in vitro migra-
tion assay and compared to the mock control, the RNAi
of uPAR (−20 %, p = 0.003), of IGF1R (−25 %, p = 0.002)
and of both receptors (−28 %, p = 0.027) or of IGF1R with
uPA (−30 %, p < 0.001) significantly diminished the in
vitro migration (Fig. 2c, right). Compared to BT549 mock
control cells, the in vitro migration was significantly re-
duced following uPAR RNAi (−20 %, p = 0.001) or co-
RNAi of uPA and IGF1R (−22 %, p = 0.001) as well as fol-
lowing co-RNAi of uPA and IGF1R (−22 %, p = 0.010)
(Fig. 2c, right, 24 h after starting the assay). Compared to
IGF1R RNAi alone, after the co-RNAi of uPAR and IGF1R
(−16 %) the in vitro BT549 cell migration was additively
reduced but not statistically significant (Fig. 2c, right, 24 h
after starting the assay). Regarding the effects 48 h after
starting the in vitro migration assay and compared to the
mock control, the RNAi of uPA has a significant and redu-
cing effect on in vitro BT549 cell migration (−15 %, p =
0.015), as well as the co-RNAi of IGF1R with uPAR or
uPA (−28 % or −20 %, p = 0.001, respectively; Fig. 2c,
right).
Concerning in vitro cell invasion, compared to MDA-
MB-231 mock control cells, the RNAi of IGF1R signifi-
cantly impaired cell invasion (−30 %, p = 0.006, Fig. 2d,
left). Compared to RNAi of uPAR or IGF1R alone, the
co-RNAi of uPAR and IGF1R significantly and additively
reduced cell invasion (−65 % or −45 % respectively, p =
0.001) and showed the strongest effect of the analysed
approaches (Fig. 2d, left). In BT549 cells, the in vitro cell
invasion was not changed following RNAi of the target
proteins or was elevated due to uPA RNAi (Fig. 2d,
right).
In summary, the long-term RNAi of IGF1R and the
combined RNAi with uPAR led to the most efficient re-
duction of in vitro proliferation, migration and invasion
in both TNBC cell lines.
uPAR directly interacts with uPA and with IGF1R in vitro
Following the optimisation of immunoprecipitation proto-
cols for uPAR and interaction partners in MDA-MB-231
cells, uPA, which is already known as a direct interactor of
uPAR, was successfully precipitated (Fig. 3a). Based on
this, novel direct uPAR interaction partners could be de-
tected in MDA-MB-231 cell lysates. IGF1R has also been
shown to be associated with uPAR and to promote cellular
(See figure on previous page.)
Fig. 2 Co-RNAi of uPAS components and of IGF1R significantly reduces malignancy of BT549 and MDA-MB-231 cells. a Representative immunoblottings
of uPAR, uPA (supernatant), IGF1R, GAPDH, (phospho) c-Met, MMP2, (phospho) 44/42 MAPK and p27Kip1 are shown. Tubulin was used as loading control.
b WST-1 assay was conducted 48 h (n= 5), c Scratch wound assays 24 h and 48 h (n= 3), d Matrigel invasion assays were conducted 48 h after starting
the experiment (n= 3). The quantifications were determined relative to mock
a uPAR and uPA interaction
L
co-IP
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Fig. 3 uPAR directly interacts with uPA and IGF1R. a Western blot analyses of co-immunoprecipitation replicates (co-IP 1–3) of uPAR with uPA or
with IGF1R (c), the lysate (L) of MDA-MB-231 cells was used as positive control and a non-targeting isotype antibody was used as negative control (NK)
b PLA and quantification of protein-protein complexes of uPAR with uPA or with IGF1R (d) on cell block sections from mock and uPAR-depleted
cells (uPAR-RNAi)
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invasion and migration in cancer cells of the pancreas
and colon as well as of rhabdomyosarcoma cells in vitro
[34–36]. Here, using further optimised protocols for immu-
noprecipitations, the direct interaction of uPAR with IGF1R
could be demonstrated (Fig. 3c). Furthermore, a relatively
new technology for the visualisation of interactions based
on formation of protein-protein complexes, the proximity
ligation assay (PLA), was conducted on FFPE sections
derived from mock and uPAR-depleted MDA-MB-231 cells
(Additional file 4: Figure S3a). Using PLA, the complexes of
uPAR with uPA could be shown and their number was
reduced following uPAR RNAi (Fig. 3b). Moreover, the
complex formation of uPAR with IGF1R was successfully
demonstrated and their number was significantly decreased
when uPAR was downregulated (−62 %, p = 0.001, Fig. 3d).
Weakly uPAR-positive and strongly IGF1R-positive MCF7
cells (Fig. 1c and Additional file 4: Figure S3b) or SKBR3
cells, which are almost negative for the protein expression
of both receptors (Fig. 1c and Additional file 4: Figure S3d)
were used as controls for visualisation of uPAR-IGF1R
complexes by PLA. In comparison with MDA-MB-231
mock cells, a significantly reduced number of complexes
was detected in MCF7 cells (−60 %, p = 0.001, Additional
file 4: Figure S3c) that was further reduced in SKBR3 cells
(−85 %, Additional file 4: Figure S3e).
uPAR directly interacts with uPA and with IGF1R in
tumours and promotes the malignancy of TNBC
In the TNBC cohort used for this study, several uPAS com-
ponents and tumour-relevant markers have been revealed
to be significantly co-overexpressed (Table 1). In particular,
uPAR significantly correlated with IGF1R (p = 0.0011), the
cathepsins B (p = 0.0034) and D (p = 0.0075), c-Met
(p = 0.0229), IR (0.0215) and plasminogen (p = 0.0105).
uPA significantly correlated with PAI-1 (p ≤ 0.00001), ca-
thepsin D (p = 0.0187), plasminogen (p = 0.0237) and in-
versely with Ki67 (p = 0.0004) (Table 1). IGF1R
significantly correlated with IR (p = 0.0020), cathepsin B
(p = 0.0002), plasminogen (p = 0.0237) and several other
biomarkers (Table 1). No association between breast can-
cer 1 mutation and histopathological parameters was
found. To investigate the clinical relevance of complexes
formed by uPAR with its interaction partners, such as
uPA or IGF1R in TNBC, the PLA technique was con-
ducted on 174 tumour specimens differentially expressing
these biomarkers. The higher the uPAR and IGF1R ex-
pression levels were in respective TNBC sample, the
higher was the number of uPAR-IGF1R complexes
(Fig. 4a), whereas the amount of these complexes was
diminished when both interactors were expressed at
low levels (Fig. 4b). High amounts of uPAR-IGF1R
complexes significantly correlated with histological grade
(p = 0.0019), Ki67 (p = 0.0284), cathepsin B (p = 0.0168) or
cathepsin D (p = 0.0290) (Table 2). IGF1R-uPAR
complexes inversely correlated with p27Kip1 (p = 0.0103),
uPA (p = 0.0002) and PAI-1 expression (p = 0.0001)
(Table 2). Complexes of uPAR and uPA significantly
correlated with IGF1R (p = 0.0032), cathepsin B and D
(p ≤ 0.0001, respectively) expression and inversely with
the tumour size (p = 0.0065) (Table 2).
Discussion
The triple-negative breast cancer mostly occurs in
young women representing 10–20 % of breast cancers
and shows an aggressive phenotype that is correlated
with a poor prognosis [2]. To date, these patients are
systemically treated with chemo-/radiotherapy and
surgery due to the lack of standard therapeutic targets
in TNBC, such as ER, PR or HER2 in other breast can-
cer subtypes. Therefore, novel therapeutics and thera-
peutic strategies are urgently needed. Although TNBC
is a heterogeneous disease [48], it is well known that
the major components of the uPA system including
uPA, uPAR and PAI-1 are often overexpressed in this
Table 1 Significant protein expressions of uPAS components
and tumour-associated markers

























Protein expressions were determined using IHC technique followed by
statistical analyses. Correlations of parameters marked in bold are described
within the text in more detail
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BC subtype and may be interesting candidates for tar-
geted therapies [9]. Several tumour-promoting bio-
markers such as EGFR, IGF1R, IR and c-Met are also
co-overexpressed in TNBC [3, 4, 6–8]. The scope of
this study was to demonstrate the potential of a long-
term downregulation of uPAR combined with the
downregulation of its already known and novel direct
interaction partners. Based on preliminary results de-
rived from transient knockdowns of uPAR, uPA and/
or IGF1R leading to significantly reduced in vitro pro-
liferation and metastasis, the long-term effects of
uPAR- and IGF1R-RNAi were determined in two
TNBC model cell lines after stable downregulations of
8 weeks. Since uPAR is associated to the cell mem-
brane only by a GPI anchor, for intracellular signal
transduction it has to interact with receptors contain-
ing a transmembrane domain. Since IGF1R is associ-
ated with uPAR [34, 35] and co-overexpressed in
IHC: uPAR high
Case 1a Case 2
IHC: uPAR low
b
IHC: IGF1R high IHC: IGF1R low
High number of uPAR & IGF1R complexes Less number of uPAR & IGF1R complexes
Fig. 4 The uPAR and IGF1R complexes correlate with their co-overexpression in TNBC samples. a Immunohistochemical analyses and visualisation
of uPAR and IGF1R in the same tumour sample expressing the target proteins at a high (score 3+) or (b) at a low (score 1+) level, bar: 100 μm
Table 2 Significant correlations of uPAR/IGF1R or uPAR/uPA
complexes with clinical parameters and tumour-associated
markers
PLA complexes Parameters p-values







uPAR with uPA IGF1R 0.0032
Cathepsin B ≤0.0001
Cathepsin D ≤0.0001
Tumour size 0.0065 (inverse)
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breast cancer [5, 6], here, it was downregulated in
combination with uPAR and further analysed to dem-
onstrate a direct interaction of both receptors. In
comparison to single RNAi of the receptors, mostly
the combined knockdown of uPAR and of IGF1R led
to an additively and significantly impaired in vitro pro-
liferation, migration and invasion, in particular of
MDA-MB-231 cells. The knockdown of uPA alone or
in combination with IGF1R RNAi also affected the
malignant potential in vitro; however it was not as
prominent as the combination of uPAR and IGF1R.
Regarding the knockdown effects on the expression or
phosphorylation of several tumour-associated pro-
teins, the effects were rather minor. The phosphoryl-
ation of STAT3 or Akt was not changed following
long-term knockdowns in both cell lines. Although the
in vitro proliferation and metastasis was impaired, it is
possible that after 8 weeks of downregulation, the cells
adapt to or compensate the lack of uPAR, uPA and/or
IGF1R and therefore, the effects on single proteins
could not be detected anymore. Nevertheless, in
MDA-MB-231 cells, a reduced phosphorylation of c-
Met was observed, whereas the cell cycle inhibitor
p27Kip1 was induced in both cell lines following IGF1R
downregulation alone or in combination with uPA
RNAi correlating with the results obtained from in
vitro proliferation assays. Due to the lack of ER, PR
and HER2 but strong uPAR protein expression and
exhibiting an invasive phenotype, BT549 cells may be
regarded as representative for TNBC. Concerning the
protein expressions of IGF1R, MMPs or phosphoryl-
ation of c-Met, this cell line differs from MDA-MB-
231 cells. In addition, the inhibitory knockdown ef-
fects in BT549 cells were not always comparable with
those observed in MDA-MB-231 cells. However, our
results are in agreement with previous studies demon-
strating high molecular heterogeneity in TNBC and in
numerous TNBC cell lines [48]. Nevertheless, in
BT549 cells, only the in vitro migration was signifi-
cantly impaired due to RNAi of uPAR or co-RNAi of
IGF1R with uPAR or uPA and this was confirmed by
immunoblottings showing reduced activation of the
metastasis marker MMP2. Neither comparable RNAi
studies in BT549 cells nor the combined downregulation
of uPAR with IGF1R in TNBC cell lines was demonstrated
before. For knockdown studies simultaneously targeting
uPAR, uPA or MMPs, mostly the MDA-MB-231, ZR751
or non-TNBC cell lines were applied and the combined
knockdown approaches led to significant and additive
effects regarding reduced malignancy of tumour cells
[31–33] corresponding to our results. Furthermore, al-
though the control shRNAs do not alter the RNA or pro-
tein levels of all the target proteins, the in vitro migration
and invasion assays of the control approaches show in
part unspecific results, which may be associated with
the respective cell lines or in vitro assays. Thus,
additional in vitro studies are necessary for understanding
the tumourigenic signalling cascades in TNBC cells in
more detail.
To further investigate the interactions of uPAR with
several tumour-promoting proteins, uPA was con-
firmed and IGF1R was identified as direct interactor
in the TNBC cohort and these complexes significantly
correlated with cathepsin B and D, whereas IGF1R sig-
nificantly correlated with cathepsin B and not with ca-
thepsin D. Previous studies have shown cathepsins
being correlated with uPAR or uPA and involved in
metastasizing processes of breast cancer cells [15, 49]
emphasizing the malignant potential of these interac-
tions in TNBC. Furthermore, uPA expression alone
significantly correlated with PAI-1, cathepsin D, plas-
minogen and Ki67 but not with the expression of uPAR,
cathepsin B or other clinical parameters, whereas uPA-
uPAR complexes significantly correlated with the expres-
sion of both cathepsins (B and D), IGF1R and in-
versely with the tumour size. For the latter
correlation we hypothesise a metastasizing effect
when the amount of uPAR-uPA complexes is ele-
vated and tumour cells migrate and spread into dif-
ferent organs leading to cell loss within the primary
tumour tissue and therefore to a reduced tumour
size. IGF1R and uPAR complexes inversely correlated
with uPA or PAI-1 expression. This outcome may
result from competing impact on the binding site for
IGF1R, uPA or PAI-1 with uPAR [50]. The outcomes
derived from PLA analyses and statistical correlations with
tumour-relevant parameters indicate that not only the
overexpression of tumour-promoting markers influences
malignancy in TNBC but their interactions with other bio-
markers may increase the malignant potential of tumour
cells. The idea to impede the interactions of uPAR with
uPA or IGF1R, as demonstrated by us, using the com-
bined knockdown of the target proteins and leading to de-
creased malignancy in vitro may be thinkable for the
future, to inhibit tumour progression in vivo by treating
TNBC patients with inhibitors targeting these biomarkers
in combination. However, further experiments including
in vivo animal studies and clinical trials are necessary to
endorse our hypothesis.
Conclusions
The overexpression of tumour-promoting biomarkers im-
pacts malignancy in TNBC but their interactions with other
signalling proteins may stronger influence the malignant
potential of tumour cells. Impeding the complexes of uPAR
with uPA or IGF1R may also strongly inhibit tumour pro-
gression in vivo by treating TNBC patients with inhibitors
targeting these biomarkers in combination.
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Additional file 1: Table S1. Overview of applied primary antibodies for
immunohistochemical analyses (IHC) and Western blots (WB). (DOC 53 kb)
Additional file 2: Figure S1. Combined RNAi of uPAR and uPA
significantly reduced the tumourigenic potential of TNBC cells. a:
Representative Western blot analysis of uPAR and uPA following RNAi
using three different siRNAs per target protein, respectively and of (b)
MMP2 and 9, (phospho) STAT3, Paxillin. Tubulin was used as loading
control. c: In vitro viability assays (n = 5), d: scratch wound assays (n = 3)
and (e) matrigel invasion assays (n = 3) are shown 48 h post-transfection.
siRNAs for transient downregulations of target proteins or of GAPDH
(positive control) and a non-targeting siRNA as negative control were used
in triplicates according to previous protocol [37]. The quantifications were
determined in relation to mock. Standard deviations and p-values are
shown. (PDF 329 kb)
Additional file 3: Figure S2. Combined RNAi of uPAR and IGF1R
significantly reduced the tumourigenic potential of TNBC cells. a:
Representative Western blot analysis of uPAR and IGF1R following RNAi
using three different siRNAs per target protein, respectively and of (b)
MMP2 and MMP9. Tubulin was used as loading control. c: In vitro viability
assays (n = 5), d: scratch wound assays (n = 3) and (e) matrigel invasion
assays (n = 3) are shown 48 h post-transfection. siRNAs for transient
downregulations of target proteins or of GAPDH (positive control) and a
non-targeting siRNA as negative control were used in triplicates according
to previous protocol [37]. f: Relative mRNA levels of uPAR, IGF1R and uPA
following stable RNAi of target proteins determined by qRT-PCR (n = 3) are
shown. The quantifications were determined in relation to mock control.
Standard deviations and p-values are shown. (PDF 336 kb)
Additional file 4: Figure S3. Immunohistochemical analysis and PLA of
uPAR and IGF1R in MDA-MB-231 and control cells. a: Differential protein
expressions of uPAR or IGF1R in mock and uPAR-depleted MDA-MB-231
cells or in MCF7 (b) and SKBR3 (d) cells. c: Visualization and quantification
of uPAR and IGF1R complexes in MCF7 and in SKBR3 (e) cells.
(PDF 658 kb)
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